ArticleInternational journal of cancer2026
Cumulative exposure to tacrolimus is associated with increased risk of malignancy for solid organ transplant recipients.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer Risk After Simultaneous Pancreas-Kidney Transplantation Compared With Kidney Transplant Alone: A Propensity-Matched Cohort Study.Clinical transplantation · 2026Article
- Cumulative exposure to tacrolimus is associated with increased risk of malignancy for solid organ transplant recipients.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Solid organ transplant recipients (SOTR) face elevated cancer risk due to prolonged immunosuppression. While higher tacrolimus exposure has been linked to de novo malignancies, the dose-response relationship remains unclear, prompting the need for population-level, longitudinal investigations. To quantify the exposure-response relationship between tacrolimus trough level and post-transplant malignancy risk, we used a population-based cohort study using linked administrative healthcare data from Ontario, Canada. All transplant recipients from January 1, 2008 to March 1, 2020 with ≥2 serum tacrolimus levels in the first year post-transplant were included. Cumulative exposure to tacrolimus was treated as a (1) continuous variable, (2) by quartiles of exposure within the first year and (3) as time-varying exposure beyond the first year; incidence of de novo malignancy was investigated using cause-specific and subdistribution Cox regression models. Among the 5178 SOTRs, a total of 318 de novo malignancies (6.1%) and 332 deaths (6.4%) occurred. For every 20% increase in the cumulative tacrolimus trough level in the first year, a heightened risk of malignancy was observed (HR = 1.09, 95% CI: 1.02-1.17). For each 20% increase in cumulative tacrolimus trough level after 1 year, the risk of malignancy increased (HR = 1.08 [95% CI: 1.01-1.15]). Patients in the highest quartile of cumulative exposure (median 9-10 ng/mL) had a 47% greater risk of malignancy compared to those in the lowest quartile (median 5-6 ng/mL; HR = 1.47 [95% CI: 1.03-2.11]). These findings highlight the importance of carefully titrating tacrolimus and avoiding unnecessary prolonged high exposure, particularly during the critical first year post-transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.